EUVIMEDEUVIMED entdecken
Open Access

Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy

Xiuting Liu iD, John M Baer, Meredith L Stone iD, Brett L Knolhoff iD, Graham D Hogg iD, Madeleine C Turner iD, Yu-Lan Kao iD, Alyssa G Weinstein iD, Faiz Ahmad iD, Jie Chen, Andrew D Schmidt iD, Jeffrey A Klomp iD und 9 weitere

Science Translational Medicine · 23.10.2024 · 16 (770)

DOI: 10.1126/scitranslmed.ado2402 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 23.10.2024. Verfasst von Xiuting Liu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is often resistant to therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations in KRAS have both been implicated as drivers of resistance to therapy. Mitogen-activated protein kinase (MAPK) inhibition has not yet shown clinical efficacy, likely because of rapid acquisition of tumor-intrinsic resistance. However, the unique PDAC TME may also be a driver of resistance. We found that long-term focal adhesion kinase (FAK) inhibitor treatment led to hyperactivation of the RAS/MAPK pathway in PDAC cells in mouse models and tissues from patients with PDAC. Concomitant inhibition of both FAK (with VS-4718) and rapidly accelerated fibrosarcoma and MAPK kinase (RAF-MEK) (with avutometinib) induced tumor growth inhibition and increased survival across multiple PDAC mouse models. In the TME, cancer-associated fibroblasts (CAFs) impaired the down-regulation of MYC by RAF-MEK inhibition in PDAC cells, resulting in resistance. By contrast, FAK inhibition reprogramed CAFs to suppress the production of FGF1, which can drive resistance to RAF-MEK inhibition. The addition of chemotherapy to combined FAK and RAF-MEK inhibition led to tumor regression, a decrease in liver metastasis, and improved survival in KRAS-driven PDAC mouse models. Combination of FAK and RAF-MEK inhibition alone improved antitumor immunity and priming of T cell responses in response to chemotherapy. These findings provided the rationale for an ongoing clinical trial evaluating the efficacy of avutometinib and defactinib in combination with gemcitabine and nab-paclitaxel in patients with PDAC and may suggest further paths for combined stromal and tumor-targeting therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDrug Resistance, NeoplasmTumor MicroenvironmentCarcinoma, Pancreatic DuctalAnimalsHumansCell Line, TumorMiceImmunotherapyras ProteinsProtein Kinase InhibitorsStromal CellsMitogen-Activated Protein KinasesCellular ReprogrammingCancer-Associated Fibroblasts

Substanzen

ras ProteinsProtein Kinase InhibitorsMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
  • Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
  • Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Verastem Oncology, Needham, MA 02494, USA.
  • Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110, USA.

ORCID-Profile: Xiuting Liu, Meredith L Stone, Brett L Knolhoff, Graham D Hogg, Madeleine C Turner, Yu-Lan Kao, Alyssa G Weinstein, Faiz Ahmad, Andrew D Schmidt, Jeffrey A Klomp, Kayjana S Coho, Jonathan A Pachter, Kirsten L Bryant, Liang-I Kang, Kian-Huat Lim, Gregory L Beatty, David G DeNardo

Förderung

  • NCI NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Liu, X., Baer, J. M., Stone, M. L., Knolhoff, B. L., Hogg, G. D., Turner, M. C., Kao, Y. L., Weinstein, A. G., Ahmad, F., Chen, J., Schmidt, A. D., Klomp, J. A., Coho, H., Coho, K. S., Coma, S., Pachter, J. A., Bryant, K. L., Kang, L. I., Lim, K. H., …, & DeNardo, D. G. (2024). Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science Translational Medicine, 16(770). https://doi.org/10.1126/scitranslmed.ado2402

Vancouver

Liu X, Baer JM, Stone ML, Knolhoff BL, Hogg GD, Turner MC, et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science Translational Medicine. 2024;16(770). doi:10.1126/scitranslmed.ado2402

BibTeX
@article{Liu2024,
  author = {Liu, Xiuting and Baer, John M and Stone, Meredith L and Knolhoff, Brett L and Hogg, Graham D and Turner, Madeleine C and Kao, Yu-Lan and Weinstein, Alyssa G and Ahmad, Faiz and Chen, Jie and Schmidt, Andrew D and Klomp, Jeffrey A and Coho, Heather and Coho, Kayjana S and Coma, Silvia and Pachter, Jonathan A and Bryant, Kirsten L and Kang, Liang-I and Lim, Kian-Huat and Beatty, Gregory L and DeNardo, David G},
  title = {Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {770},
  doi = {10.1126/scitranslmed.ado2402}
}
Kostenlos starten →